OBJECTIVE: Prostate cancer (PC) model systems that reflect the different disease stages are essential for studying the development and progression of PC and for testing new treatment modalities. This review summarizes the establishment and characterization of the PC346 progression model and compares it to other available human PC cell lines and xenografts. METHODS: The PC346 model was derived from the transurethral resection of a primary prostate tumor. Tumor samples were subcutaneously implanted into athymic mice, which resulted in the development of a series of xenografts from which in vitro cell cultures were established. RESULTS: The PC346 panel includes sublines with hormone-response characteristics that range from androgen-sensitive to androgen-independent (AI) growth. In vivo and in vitro selection of androgen-sensitive lines under androgen-depleted conditions replicated the clinically relevant relapse phenomenon, and resulted in a series of modifications in the androgen-receptor (AR) pathway: AR mutation, overexpression, and downregulation. CONCLUSIONS: The PC346 panel reproduces many biological characteristics of the different phases of clinical PC and the most common AR modifications observed in hormone-refractory tumors, being a valuable addition to the limited collection of available model systems.
OBJECTIVE:Prostate cancer (PC) model systems that reflect the different disease stages are essential for studying the development and progression of PC and for testing new treatment modalities. This review summarizes the establishment and characterization of the PC346 progression model and compares it to other available human PC cell lines and xenografts. METHODS: The PC346 model was derived from the transurethral resection of a primary prostate tumor. Tumor samples were subcutaneously implanted into athymic mice, which resulted in the development of a series of xenografts from which in vitro cell cultures were established. RESULTS: The PC346 panel includes sublines with hormone-response characteristics that range from androgen-sensitive to androgen-independent (AI) growth. In vivo and in vitro selection of androgen-sensitive lines under androgen-depleted conditions replicated the clinically relevant relapse phenomenon, and resulted in a series of modifications in the androgen-receptor (AR) pathway: AR mutation, overexpression, and downregulation. CONCLUSIONS: The PC346 panel reproduces many biological characteristics of the different phases of clinical PC and the most common AR modifications observed in hormone-refractory tumors, being a valuable addition to the limited collection of available model systems.
Authors: A Schäfer; A Pahnke; D Schaffert; W M van Weerden; C M A de Ridder; W Rödl; A Vetter; C Spitzweg; R Kraaij; E Wagner; Manfred Ogris Journal: Hum Gene Ther Date: 2011-08-10 Impact factor: 5.695
Authors: Flip H Jansen; Jeroen Krijgsveld; Angelique van Rijswijk; Gert-Jan van den Bemd; Mirella S van den Berg; Wytske M van Weerden; Rob Willemsen; Lennard J Dekker; Theo M Luider; Guido Jenster Journal: Mol Cell Proteomics Date: 2009-02-09 Impact factor: 5.911
Authors: Rute B Marques; Natasja F Dits; Sigrun Erkens-Schulze; Wytske M van Weerden; Guido Jenster Journal: PLoS One Date: 2010-10-19 Impact factor: 3.240
Authors: Maria Prencipe; Amanda O'Neill; Gillian O'Hurley; Lan K Nguyen; Aurelie Fabre; Anders Bjartell; William M Gallagher; Colm Morrissey; Elaine W Kay; R William Watson Journal: Prostate Date: 2015-08-07 Impact factor: 4.104
Authors: Albertus W Hensbergen; Tessa Buckle; Danny M van Willigen; Margret Schottelius; Mick M Welling; Felicia A van der Wijk; Tobias Maurer; Henk G van der Poel; Gabri van der Pluijm; Wytske M van Weerden; Hans-Jürgen Wester; Fijs W B van Leeuwen Journal: J Nucl Med Date: 2019-09-03 Impact factor: 10.057